Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest Labs releases data on Ceftaroline

Forest Labs releases data on Ceftaroline

31st October 2008

Forest Laboratories has released new data on its Canvas I phase III clinical trial, which demonstrated ceftaroline monotherapy reaching its primary endpoint.

It also presented abstracts from preclinical studies, showing the activity of ceftaroline versus multi-drug-resistant Steptococcus pneumonia, MRSA (methicillin-resistant Staphylococcus aureus) and other gram-negative pathogens.

The results of the Canvas I trial found that ceftaroline, which is a novel broad-spectrum cephalosporin for complicated skin and skin structure infection (cSSSI), had a clinical cure rate of 91.1 per cent when compared to a 93.3 per cent clinical cure rate from vancomycin-plus-aztreonam in the clinically evaluable population.

These figures were 86.6 per cent compared to 85.6 per cent in the modified-intent-to-treat population of the study.

Dr G Ralph Corey, director of clinical diseases at the Duke Clinical Research Institute, said the statistics “add to the growing scientific evidence that support ceftaroline as a potential novel treatment for cSSSIs.

“These results are important because we see a growing number of infections, including many with difficult-to-treat organisms. Clearly new options are needed to optimize our current treatment capabilities,” he added.

Forest Laboratories was founded in 1954 and is headquartered in New York City, US.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.